期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

瑞舒伐他汀对慢性心力衰竭患者心房颤动的预防作用 被引量：12

暂未订购
导出
摘要 慢性心力衰竭（心衰）患者伴有心房颤动（房颤）通常会增加病死率和脑栓塞的发生率。房颤时心率增快和心房收缩功能丧失，导致心排血量显著减少，进而加重心衰患者心肌缺血性损伤。最近的研究显示，在没有心血管疾病、LDL—C正常，但C反应蛋白升高的患者中，使用瑞舒伐他汀可以使心血管死亡、心肌梗死、脑卒中等首要终点降低44％。
作者 玄春花 杨光 于治利
机构地区 延边大学附属医院心内科
出处 《中华老年心脑血管病杂志》 CAS 北大核心 2010年第5期470-470,共1页 Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词 慢性心力衰竭患者 瑞舒伐他汀 心房颤动 预防作用 心肌缺血性损伤 C反应蛋白升高 心血管疾病 心衰患者
分类号 R541.6 [医药卫生—心血管疾病] R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献3

  • 1Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med,2008,359:2195-2207.
  • 2王政,杨树森,陈红丽,李为民,周宏艳.瑞苏伐他汀和阿托伐他汀治疗对冠心病患者妊娠相关血清蛋白A的影响[J].中华老年心脑血管病杂志,2009,11(8):584-587. 被引量：5
  • 3Maggioni AP,Latini R,Carson PE,et al.Valsartan reduces the incidence of atrial fibrillation in patients with heart failure results from the Valsartan Heart Failure Trial(Val-HeFT).Am Heart J,2005,149:548-557.

二级参考文献14

  • 1Saenger AK,Jaffe AS. The use of biomarkers for the evaluation and treatment of patients with acute coronary syndromes. Med Clin North Am, 2007,91 :657-681.
  • 2Qin QP, Kokkala S, Lund J, et al. Immunoassays developed for pregnancy-associated plasma protein-A(PAPP-A) in pregnancy may not recognize PAPP-A in acute coronary syndromes. Clin Chem, 2006,52 : 398-404.
  • 3Thorn EM,Khan IA. Pregnancy-associated plasma protein-A: an emerging cardiac biomarker, Int J Cardiol, 2007,117:370-372.
  • 4Hajek P, Macek M, Hladikova M, et al. Pregnancy-associated plasma protein A and proform eosinophilie major basic protein in the detection of different types of coronary artery disease. Physiol Res, 3008,57 : 23-32.
  • 5Qin QP,Wittfouth S, Pettersson K. Measurement and clinical significance of circulating PAPP-A in ACS patients. Clin Chim Acta,2007,380:59-67.
  • 6Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hsCRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes:results from PROVE IT-T1MI 22. Arterioscler Thromb Vasc Biol, 2009,29:424-430.
  • 7Smith CL. C-reactive protein and asymmetric dimethylarginine:markers or mediators in cardiovascular disorders? Curr Pharm Des,2007,13: 1619-1629.
  • 8de Ferranti SD, Rifai N. C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol, 2007,16 : 14-21.
  • 9Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation, 2007, 115 : 1528-1536.
  • 10Meredith KG, Home BD, Pearson RR, et al. Comparison of effects of high(80 rag) versus low(20 mg) dose of simvastatin on'C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. Am J Cardiol, 2007,99 : 149-153.

同被引文献111

引证文献12

二级引证文献114

中华老年心脑血管病杂志
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部